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RHealth-Related Quality
of Life After Transcatheter
Aortic Valve Replacement
With great interest we read the recent report by Reynolds et al. (1)
reporting on the health-related quality-of-life (HRQOL) out-
comes in Cohort A of the PARTNER (Placement of Aortic
Transcatheter Valves) randomized controlled trial. Using 3 differ-
ent standardized questionnaires at 1, 6, and 12 months, HRQOL
was analyzed in a total of 628 patients with severe, symptomatic
aortic valve stenosis at high surgical risk who were randomized to
transcatheter aortic valve replacement (TAVR) via the transapical
or transfemoral approach or to surgical aortic valve replacement
(SAVR). Health status improved substantially between baseline
and 1 year after both TAVR and SAVR. TAVR via the trans-
femoral but not the transapical route was associated with short-
term advantages compared with surgery. Although evidence is
accumulating that patients at high risk for SAVR undergoing
TAVR derive HRQOL benefits, the investigators should be
commended for this important study, because it represents the first
randomized study investigating HRQOL dynamics after TAVR in
comparison with SAVR, adding an important piece of evidence to
the field.
We would greatly appreciate the investigators’ comments on
how New York Heart Association functional class developed over
time. As long as valve function is durable, one would expect that
functional benefits can be maintained in the longer term as well.
However, data derived from Cohort B of the PARTNER trial and
other studies suggest that functional status slightly worsens at 12
months (2–4). We concur with the investigators that the results of
available studies encompass only a maximal follow-up period of 1
year, which may be too short. Therefore, the longer term dynamics
of HRQOL changes in TAVR patients remain elusive.
Did the investigators attempt to evaluate and correlate
HRQOL outcomes with New York Heart Association functional
class or with any of the baseline characteristics? The identification
of patient-related or procedure-related parameters predictive of the
extent of HRQOL benefits would be highly desirable to facilitate
better risk stratification and patient selection and to improve
guidance of patient-centered clinical decision making. It has been
observed that the extent of benefit seems to be inferior for patients
with oxygen-dependent chronic obstructive pulmonary disease (2).
Also, lower operator experience, female sex, and vascular compli-
cations have been reported to be independent predictors of lower
HRQOL improvements at 1 year (3). In our prospective cohort,
mitral valve regurgitation I° was predictive of lower HRQOL
improvements. Only at 3 months did this association reach
statistical significance. Likewise, female sex was associated with
less improvement at 3 months, corroborating the results described
by Fairbairn et al. (3). Notably, we could not observe anyassociation with Society of Thoracic Surgeons score or log Euro-
pean System for Cardiac Operative Risk Evaluation score, hemo-
dynamic parameters, or comorbidities (4).
Larger patient numbers in conjunction with longer follow-up
will be necessary to identify reliable patient-related and procedure-
related factors predictive of the extent of HRQOL benefits and to
answer the question of whether benefits are durable conclusively.
In the future, it will be of interest to determine how HRQOL
benefits compare between TAVR and SAVR in patients at lower
surgical risk (5).
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Reply
We agree with many of the points raised in the letter by Dr.
Deutsch and colleagues and appreciate their interest in our work.
We have not as yet made any formal correlations between
patient-level health status measures and New York Heart Associ-
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January 8, 2013:108–11ation functional class using the PARTNER (Placement of Aortic
Transcatheter Valves) data, but we would expect them to move in
directionally similar ways, particularly for measures such as the
physical component score of the SF-12 or SF-36. Longer term
quality-of-life data from the PARTNER program are being
collected but are not yet available for analysis. In the meantime,
New York Heart Association data through 2 years have been
reported for both the inoperable (2) and high-risk surgical candi-
date populations (3). These reports show that about 85% of 2-year
survivors were in New York Heart Association functional class I or
II after either transcatheter aortic valve replacement (TAVR) or
aortic valve replacement, with no suggestion of deterioration from
year 1 to year 2. However, these analyses of survivors may be
affected by attrition of the sickest patients over time. Given the age
and medical complexity of patients currently undergoing TAVR, it
would not be surprising to see some decline in functional status
and quality of life over time, as observed with aging in general, and
as suggested in a UK analysis of TAVR patients limited to those
who completed surveys at all 4 time points in the first year (4). We
agree that the identification of baseline patient factors that reliably
predict changes in health status after TAVR (or aortic valve
replacement) would aid in refining patient selection for these
interventions and should be the focus of subsequent investigations.
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Outcomes of Atrial Fibrillation
Ablation in Patients With
Metabolic Syndrome
We read with interest the paper by Mohanty et al. (1), which
demonstrates a strong association between metabolic syndrome(MS) and recurrence of atrial fibrillation after catheter ablation
(AFCA) but only in patients with nonparoxysmal atrial fibrillation
(NPAF).
Recently, we presented the data of 5-year follow-up in a group
of 702 patients after both radiofrequency and cryoballoon AFCA
that proved MS to be the independent predictor of atrial fibrilla-
tion (AF)-free survival AFCA, regardless of left atrium size (LAS),
type of AF, and energy source used (2). Patients with MS were
1.32 more likely to have AF recurrence than patients without
MS. Median time to AF recurrence AFCA was 18.6 months in
patients with MS and 28.6 months in patients without MS
(p  0.011) (Fig. 1). Similar results were published by others
3,4), and the discrepancy had already been mentioned by Asir-
vatham and Jiao (5). Interestingly, our data showed that MS had
no impact on outcome after re-do pulmonary vein isolation, which
might support the editorial comment: “perhaps we learned that
trigger elimination, even if in 1-time procedure, can be effective
despite an ongoing primary arrhythmia-provoking process” (5).
The contradictory findings by Mohanty et al. (1) might be
in part) explained by several limitations of their study. First, the
resented study group was not as homogenous as ours, with
ignificant differences in LAS and upstream therapy drugs. The
AS is known to be one of the strongest predictors of outcome
fter AF ablation (6). If LAS was significantly bigger in NPAF
ithout MS, the expected results could have been as described by
nvestigators (1). Renin-angiotensin-aldosterone system blockers
protect from AFCA in patients with PAF (7). Most of the patients
with MS (82%) received angiotensin-converting enzyme inhib-
itors compared with patients without MS (28%). If the similar
proportion was in the PAF group, we could have expected
better outcome in patients with MS (i.e., no significant differ-
ence as described) (1). The role of statins post-pulmonary vein
solation has not been established (6), but the published
meta-analysis reported statins to be more effective for preven-
tion of PAF (8). Again, a higher number of patients with MS
91%) received lipid-lowering therapy than patients without
S (30%). Second, the results should be checked—keeping in
ind the noncompletely homogenous study group—with a
ropensity score matching, which allows for analysis in a
ell-balanced cohort. It would be interesting to know whether
ohanty et al. (1) would reach the same results in the
well-matched samples. Third, the follow-up period was (only)
21  7 months. The difference in the outcome AFCA in patients
with and without MS becomes even more significant within longer
follow-up, both in PAF and NPAF groups (2).
Following the latest recommendations (6), we think that it is
important to recognize that AF recurrence rates AFCA depend on
concomitant diseases, and outcome of AFCA in patient popula-
tions not well-represented in clinical trials should be reported.
Patients with MS are such a population. Therefore, further
discussion and clear data presentation are needed to solve the
discrepancy in reported results.
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